All news

Prothena development chief exits for partner role

Alpha Vantage · ad-hoc-news.de · · AI-summarised by FinFlash

Prothena's chief development officer Chad Swanson resigned effective October 9, 2026, to lead a partnered program with a strategic partner, preserving a collaboration link for the clinical-stage biotech. The company reported Q2 2026 revenue of

Read original source

PRTA company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.